An observational study in Alzheimer's Disease, sponsored by Shanghai Mental Health Center. Not yet recruiting. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Shanghai Mental Health Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This observational study aims to understand the efficacy, adverse reactions and costs of three different drug mechanisms used to treat dementia in patients with Alzheimer's disease, over a period of 2 years.
Alzheimer's disease (AD) imposes a heavy disease burden. Pharmacoeconomic evaluation is crucial for the rational clinical use of drugs and the allocation of medical resources. Currently, the research and development of innovative drugs represented by Aβ-targeted monoclonal antibodies are in full swing. Although various drugs used to improve cognitive impairment in AD have significant therapeutic advantages in clinical practice, due to the different durations of their clinical applications, their economic benefits and risk assessments remain insufficient.
This study, based on decision tree models, integrates multi-source data to conduct multi-dimensional cost analyses of three categories of drugs and explores the influencing factors. The aim is to provide evidence for clinical medication and health insurance policy-making, fill the gap in the pharmacoeconomic research of new drugs, and promote the development of the AD treatment field.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
This study's planned enrollment of 150 is below the median of 200 across 815 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Shanghai Mental Health Center is the lead sponsor of 274 studies on the registry; 93 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients aged 50-85 years with mild to moderate Alzheimer's disease-related cognitive impairment receiving continuous anti-dementia pharmacotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incremental Cost-Effectiveness Ratio
Incremental cost-effectiveness ratio calculated across three drug groups for Alzheimer's disease cognitive impairment.
Time frame: 2028.4
Change in ADAS-Cog13
Change from baseline in ADAS-Cog13 cognitive scores
Time frame: 2028.4
Proportion of Participants With Adverse Events
proportion of participants with adverse events, compared across three drug groups.
Time frame: 2028.4
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 16 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →